Solange Peters, MD, PhD, is a full professor, and chair of medical oncology and the thoracic malignancies programme in the Department of Oncology at the University Hospital of Lausanne in Lausanne, Switzerland. She received both her doctorate in medicine and PhD from the University Hospital of Lausanne. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Prof. Peters specialised in thoracic tumours, lung cancer, and pleural tumours.

Prof. Peters is currently in charge of teaching and patient care in thoracic malignancies at Lausanne University, where she is building a translational programme in collaboration with the Swiss Federal Institute of Technology and the Ludwig Institute. Her main fields of interest are new biomarker discovery and validation in preclinical and clinical settings, multimodality strategies for locally advanced non-small cell lung cancer (NSCLC), as well as cancer immunotherapy. Her current research projects are mainly focused on innovative immunotherapy combinations and new immunomodulating treatments across thoracic malignancies. She acts as the local principal investigator (PI) for lung trials opened at Lausanne Cancer Centre and is a co-PI of several other trials. Additionally, she acts as the scientific committee chair and Foundation Council member of the European Thoracic Oncology Platform. She was recently nominated as the Strategic Advisory Board President of the Paris Saclay Cancer Cluster and is part of the Board of Directors of the Swiss National Cancer League.

Prof. Peters has authored more than 500 peer-reviewed manuscripts and book chapters, acts as Associate Editor of the Annals of Oncology, Deputy Editor of Lung Cancer, and serves on the editorial board of several other oncology journals. She was the deputy editor of the Journal of Thoracic Oncology for 10 years. Prof. Peters is active in the educational programmes of the European Society for Medical Oncology (ESMO), where she created the Women for Oncology Committee and for which she was the youngest President ever for an extended time of 3 years 2020-2022, and the International Association for the Study of Lung Cancer (IASLC), where she was a member of the Board of Directors.